2010
The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development
Kidd M, Siddique ZL, Drozdov I, Gustafsson BI, Camp RL, Black JW, Boyce M, Modlin IM. The CCK2 receptor antagonist, YF476, inhibits Mastomys ECL cell hyperplasia and gastric carcinoid tumor development. Peptides 2010, 162: 52-60. PMID: 20144901, DOI: 10.1016/j.regpep.2010.01.009.Peer-Reviewed Original ResearchConceptsECL cell hyperplasiaECL cell secretionCell secretionCell hyperplasiaTumor developmentReceptor antagonistGastric ECL cell carcinoidsRodent speciesECL cell functionECL cell neoplasiaECL cell tumorsGastric neuroendocrine tumorsECL cell carcinoidsCell proliferationTumor formationAutocrine growth factorCCK2 receptor antagonistECL cell proliferationCell functionGrowth factorCarcinoid developmentAcid suppressionAtrophic gastritisCell carcinoidCell tumors
2006
Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development
Kidd M, Modlin IM, Eick GN, Camp RL, Mane SM. Role of CCN2/CTGF in the proliferation of Mastomys enterochromaffin-like cells and gastric carcinoid development. AJP Gastrointestinal And Liver Physiology 2006, 292: g191-g200. PMID: 16950763, DOI: 10.1152/ajpgi.00131.2006.Peer-Reviewed Original ResearchConceptsNormal ECL cellsECL cell proliferationECL cell preparationCell proliferationNormal mucosaECL cellsEnterochromaffin-like cell proliferationERK1/2 phosphorylationERK1/2 inhibitor PD-98059Enterochromaffin-like cellsShort-term cultured cellsCell preparationsCCN2 proteinPD 98059Tumor cell proliferationCarcinoid developmentGastrin regulationGastric carcinoidsMitogenic growth factorsReal-time PCRGastric mucosaNeoplastic proliferationInhibitor PD 98059Carcinoid tissueECL cell transformationMolecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable Prognosis
Weinberger PM, Yu Z, Haffty BG, Kowalski D, Harigopal M, Brandsma J, Sasaki C, Joe J, Camp RL, Rimm DL, Psyrri A. Molecular Classification Identifies a Subset of Human Papillomavirus–Associated Oropharyngeal Cancers With Favorable Prognosis. Journal Of Clinical Oncology 2006, 24: 736-747. PMID: 16401683, DOI: 10.1200/jco.2004.00.3335.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaHuman papillomavirusFavorable prognosisClass IIILocal recurrencePrognostic valueHuman Papillomavirus–Associated Oropharyngeal CancerHPV DNA presenceHPV16 viral loadDisease-free survivalMultivariable survival analysisSquamous cell carcinomaLong-term patientsThree-class modelReal-time polymerase chain reactionHPV statusLow p53Only patientsOverall survivalOropharyngeal cancerViral loadCell carcinomaPolymerase chain reactionClinical trialsP16 overexpression
2003
ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer.
Garcia-Rostan G, Zhao H, Camp RL, Pollan M, Herrero A, Pardo J, Wu R, Carcangiu ML, Costa J, Tallini G. ras mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancer. Journal Of Clinical Oncology 2003, 21: 3226-35. PMID: 12947056, DOI: 10.1200/jco.2003.10.130.Peer-Reviewed Original ResearchConceptsThyroid carcinomaResult of diseasePoor prognosisRas mutationsTumor differentiationK-ras codon 13 mutationDifferentiated thyroid carcinomaCodon 13 mutationsAggressive cancer behaviorAggressive tumor phenotypeFollicular cell derivationN-ras mutationsClinicopathologic featuresIndependent predictorsUndifferentiated carcinomaThyroid cancerPoor survivalUndifferentiated tumorsPatientsCarcinomaActivating mutationsCancer behaviorSignificant associationTumorsRas tumors